KRYS - Krystal Biotech secures $125 capital via equity raise

Krystal Biotech (KRYS) has priced its public offering of ~1.9M common shares at $65.00/share, for expected gross proceeds of ~$125M.Underwriters' over-allotment is an additional 288,461 shares. Net proceeds will be used for development and commercialization of drug candidates; to complete development of manufacturing facility for scale-up production of pipeline compounds; for working capital and general corporate purposes.Closing date is February 5.Shares down 4.6% after-hours.Previously (Feb. 2): Krystal Biotech to raise $100M in stock offering

For further details see:

Krystal Biotech secures $125 capital via equity raise